CY1122745T1 - Εμβολιο βιοχημικως σταθεροποιημενου τριμερους μανδυα hiv-1 - Google Patents

Εμβολιο βιοχημικως σταθεροποιημενου τριμερους μανδυα hiv-1

Info

Publication number
CY1122745T1
CY1122745T1 CY20201100062T CY201100062T CY1122745T1 CY 1122745 T1 CY1122745 T1 CY 1122745T1 CY 20201100062 T CY20201100062 T CY 20201100062T CY 201100062 T CY201100062 T CY 201100062T CY 1122745 T1 CY1122745 T1 CY 1122745T1
Authority
CY
Cyprus
Prior art keywords
hiv
biochemically
trimer
vaccine
covered
Prior art date
Application number
CY20201100062T
Other languages
English (en)
Inventor
Stephen C. Harrison
Bing Chen
Dan H. Barouch
Joseph P. Nikolola
Michael Scott Seaman
Original Assignee
Children's Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Medical Center Corporation filed Critical Children's Medical Center Corporation
Publication of CY1122745T1 publication Critical patent/CY1122745T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect

Abstract

Παρέχονται σταθεροποιημένα τριμερή ενός στελέχους του κλάδου Α και ενός στελέχους του κλάδου C του HIV-1. Παρέχονται επίσης οι μέθοδοι για την ευρέως εξουδετέρωση των αντιορών κατά του HIV-1, την παραγωγή των ευρέως εξουδετεροποιημένων αντιορών κατά του HIV-1, την ευρέως εξουδετέρωση εμβολίων κατά του HIV-1, καθώς και οι μέθοδοι για τη θεραπεία των υποκειμένων που είναι μολυσμένα με HIV, την πρόληψη της μόλυνσης με HIV και την αναστολή των δράσεων μέσω του HIV.
CY20201100062T 2008-10-10 2020-01-23 Εμβολιο βιοχημικως σταθεροποιημενου τριμερους μανδυα hiv-1 CY1122745T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10444908P 2008-10-10 2008-10-10
EP09820044.7A EP2340038B1 (en) 2008-10-10 2009-10-13 Biochemically stabilized hiv-1 env trimer vaccine
PCT/US2009/060494 WO2010042942A2 (en) 2008-10-10 2009-10-13 Biochemically stabilized hiv-1 env trimer vaccine

Publications (1)

Publication Number Publication Date
CY1122745T1 true CY1122745T1 (el) 2021-01-27

Family

ID=42101262

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100190T CY1119921T1 (el) 2008-10-10 2018-02-15 Εμβολιο βιοχημικως σταθεροποιημενου τριμερους μανδυα hiv-1
CY20201100062T CY1122745T1 (el) 2008-10-10 2020-01-23 Εμβολιο βιοχημικως σταθεροποιημενου τριμερους μανδυα hiv-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181100190T CY1119921T1 (el) 2008-10-10 2018-02-15 Εμβολιο βιοχημικως σταθεροποιημενου τριμερους μανδυα hiv-1

Country Status (14)

Country Link
US (6) US9707289B2 (el)
EP (2) EP2340038B1 (el)
AU (1) AU2009303284B2 (el)
CY (2) CY1119921T1 (el)
DK (2) DK2340038T3 (el)
ES (2) ES2659875T3 (el)
HR (2) HRP20180281T1 (el)
HU (2) HUE049393T2 (el)
LT (2) LT3335728T (el)
PL (2) PL3335728T3 (el)
PT (2) PT3335728T (el)
SI (2) SI3335728T1 (el)
TR (1) TR201802130T4 (el)
WO (1) WO2010042942A2 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868651A4 (en) 2005-04-12 2010-10-06 Univ Duke METHOD FOR INDUCING ANTIBODIES THAT NEUTRALIZE THE HUMAN IMMUNODEFICIENCY VIRUS
CA2683752A1 (en) 2007-04-13 2008-10-23 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20120070488A1 (en) * 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
LT3335728T (lt) 2008-10-10 2020-03-10 Children`S Medical Center Corporation Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina
WO2010114628A2 (en) 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
US9060984B2 (en) * 2010-10-30 2015-06-23 George Dacai Liu Recombinant HIV-1 envelope proteins comprising stabilizing two-cysteine mini-domains in gp41
WO2014022475A2 (en) * 2012-08-03 2014-02-06 Dana-Faber Cancer Institute, Inc. Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
SG11201505229XA (en) * 2013-01-07 2015-08-28 Beth Israel Hospital Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
AU2014224049B2 (en) 2013-02-28 2018-11-29 Therabiol, Inc. HIV antigens and antibodies
US9675687B2 (en) 2013-03-15 2017-06-13 University Of Massachusetts Compositions and methods to treat AIDS
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
WO2015051270A1 (en) 2013-10-04 2015-04-09 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same
NZ728072A (en) 2014-07-11 2018-06-29 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
RS61902B1 (sr) 2014-09-26 2021-06-30 Beth Israel Deaconess Medical Ct Inc Metodi i kompozicije za indukovanje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
AU2016369326B2 (en) 2015-12-15 2019-02-21 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
US10273268B2 (en) 2016-06-16 2019-04-30 Janssen Vaccines & Prevention B.V. HIV vaccine formulation
AU2017318689A1 (en) 2016-09-02 2019-04-11 Beth Israel Deaconess Medical Center, Inc. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
HUE052008T2 (hu) 2016-09-15 2021-04-28 Janssen Vaccines & Prevention Bv Trimert stabilizáló HIV-burokfehérje-mutációk
US11230572B2 (en) 2016-10-17 2022-01-25 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
MA49397A (fr) 2017-06-15 2020-04-22 Bavarian Nordic As Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation
BR112020000867A2 (pt) 2017-07-19 2020-07-21 Janssen Vaccines & Prevention B.V. mutações da proteína do envelope do hiv estabilizando o trímero
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
WO2019055888A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
WO2020064621A1 (en) 2018-09-25 2020-04-02 Janssen Vaccines & Prevention B.V. Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
TW202110476A (zh) 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
IL292760A (en) 2019-11-07 2022-07-01 Janssen Vaccines Prevention B V Purification of proteins
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
EP1214333A4 (en) * 1999-09-17 2005-01-19 Dana Farber Cancer Inst Inc STABILIZED SOLUBLE GLYCOPROTEINTRIMERE
AU2003291402A1 (en) 2002-11-07 2004-06-03 Beth Israel Deaconess Medical Center MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
WO2004050856A2 (en) * 2002-12-03 2004-06-17 University Of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
US20070298051A1 (en) 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
US20080274134A1 (en) * 2004-06-15 2008-11-06 Norbert Schulke Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
JP4772045B2 (ja) * 2004-07-16 2011-09-14 アメリカ合衆国 Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
AP2351A (en) 2004-10-13 2012-01-25 Crucell Holland Bv Improved adenoviral vectors and uses thereof.
WO2007005934A2 (en) * 2005-07-06 2007-01-11 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
EP1917040A4 (en) 2005-08-23 2012-12-12 Univ California POLYVALENT VACCINE
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
EP2040747A4 (en) 2006-06-19 2010-08-25 Progenics Pharm Inc SOLUBLE STABILIZED TRIMERIC HIV ENV PROTEINS AND USES THEREOF
CA2667358A1 (en) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
LT3335728T (lt) 2008-10-10 2020-03-10 Children`S Medical Center Corporation Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina
WO2010059732A1 (en) 2008-11-18 2010-05-27 Beth Israel Deaconess Medical Center Antiviral vaccines with improved cellular immunogenicity
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
EP3556396B1 (en) 2010-08-31 2022-04-20 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
US20140348791A1 (en) 2011-09-09 2014-11-27 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2766037A4 (en) 2011-10-12 2015-08-05 Scripps Research Inst HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF
US9683268B2 (en) 2012-09-19 2017-06-20 Beth Israel Deaconess Viruses associated with immunodeficiency and enteropathy and methods using same
CA3200425A1 (en) 2012-11-16 2014-05-22 Peter ABBINK Recombinant adenoviruses and use thereof
SG11201505229XA (en) * 2013-01-07 2015-08-28 Beth Israel Hospital Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
CA2916827C (en) * 2013-07-08 2021-11-02 Novartis Ag Rotavirus particles with chimeric surface proteins
WO2015048770A2 (en) 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
US10444908B2 (en) 2016-12-31 2019-10-15 Innoventions, Inc. Virtual touchpads for wearable and portable devices

Also Published As

Publication number Publication date
DK2340038T3 (en) 2018-02-26
EP3335728A1 (en) 2018-06-20
HUE037270T2 (hu) 2018-08-28
US10307478B2 (en) 2019-06-04
TR201802130T4 (tr) 2018-03-21
AU2009303284B2 (en) 2016-01-28
WO2010042942A2 (en) 2010-04-15
US20170290907A1 (en) 2017-10-12
US20200323976A1 (en) 2020-10-15
US10463729B2 (en) 2019-11-05
EP2340038A2 (en) 2011-07-06
WO2010042942A3 (en) 2010-06-24
PL2340038T3 (pl) 2018-07-31
US20200023056A1 (en) 2020-01-23
PT2340038T (pt) 2018-02-21
SI2340038T1 (en) 2018-05-31
HRP20200370T1 (hr) 2020-06-12
EP2340038B1 (en) 2018-01-10
CY1119921T1 (el) 2018-12-12
US20190240319A1 (en) 2019-08-08
EP3335728B1 (en) 2019-12-25
US20180207259A1 (en) 2018-07-26
EP2340038A4 (en) 2012-08-15
US9707289B2 (en) 2017-07-18
US11229696B2 (en) 2022-01-25
ES2765890T3 (es) 2020-06-11
LT2340038T (lt) 2018-04-10
PL3335728T3 (pl) 2020-06-29
SI3335728T1 (sl) 2020-04-30
US9950060B2 (en) 2018-04-24
ES2659875T3 (es) 2018-03-19
DK3335728T3 (da) 2020-02-24
HUE049393T2 (hu) 2020-09-28
LT3335728T (lt) 2020-03-10
EP3335728B8 (en) 2020-03-11
US10653770B2 (en) 2020-05-19
PT3335728T (pt) 2020-02-19
HRP20180281T1 (hr) 2018-05-04
US20120045472A1 (en) 2012-02-23
AU2009303284A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
CY1122745T1 (el) Εμβολιο βιοχημικως σταθεροποιημενου τριμερους μανδυα hiv-1
CY1123237T1 (el) Αρυλο και ετεροαρυλο συμπυκνωμενες λακταμες
CY1124742T1 (el) 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv
CY1119544T1 (el) Πολυκυκλικες ενωσεις καραβαμοϋλοπυριδονης και χρηση αυτων στη θεραπεια λοιμωξεων απο hiv
CY1116602T1 (el) Παραγωγα υδροξαμικου οξεος
CY1124288T1 (el) Cmv εμβολια
CR20150454A (es) Compuestos amida para el tratamiento de vih
CY1117719T1 (el) Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2
CY1122717T1 (el) Ανασυνδυασμενος τροποπoiημενος ιος της δαμαλιτιδας της αγκυρας (mva) ως εμβολιο εναντι του αναπνευστικου συγκυτιακου ιου (rsv)
CY1119545T1 (el) Πολυκυκλικες ενωσεις καραβαμοϋλοπυριδονης και χρηση αυτων στη θεραπεια λοιμωξεων απο hiv
CY1117996T1 (el) Genz 112638 για την θεραπευτικη αγωγη της νοσου gaucher ή fabry σε θεραπεια συνδυασμου
EA202190473A2 (ru) Противовирусная терапия
CO6331439A2 (es) 1-2 bicíclicos pirimidinona carboxamida como inhibidores de la integrasa del virus de inmunodeficiencia humana
CY1117948T1 (el) Μεθοδος επαγωγης ανοχης σε ενα αλλεργιογονο
AR121361A1 (es) Vacuna
EA201290956A1 (ru) Вакцина против вич
EP2601967A4 (en) MEDICINE FOR PREVENTING AND TREATING HIV-RELATED OR HIV-RELATED DISEASES, INCLUDING AIDS
CO6650413A2 (es) Conjugador para prevención o el tratamiento de la adicción a la nicotina
CY1122367T1 (el) Διαδικασια για την αποκτηση ενεργων οπτικα εναντιομερων πιρλινδολης και των αλατων τους
CY1121564T1 (el) Σπειρο-ινδολινες για τη θεραπεια και την προφυλαξη απο τη λοιμωξη απο τον αναπνευστικο συγκυτιακο ιο (rsv)
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
DK2025750T3 (da) Targets og forbindelser til terapeutisk intervention af HIV-infektion
CL2014003549A1 (es) Producción de cultivos protozoarios de histomonas meleagridis; y formulación de vacuna que comprende un cultivo atenuado de h. meleagridis y al menos un cultivo bacteriano de una cepa única.
CY1116588T1 (el) Νεα παραγωγα 6,7-διϋποκατεστημενης-ισοκινολινης και η χρηση τους
UA117563C2 (uk) Композиція для лікування або профілактики хвороби, асоційованої з інфекцією впл